Other Cellbxhealth partners with AdventHealth on CTCbased monitoring in two major cancer studies pharminent May 18, 2026
Regulatory FDA approves Enhertu for two HER2-positive early breast cancer indications pharminent May 18, 2026
Clinical Data Biogen’s Alzheimer’s results bolster tau theory–and Denali’s next gen candidate pharminent May 15, 2026
Clinical Data ECO 2026: SURMOUNT-MAINTAIN proves tirzepatide sustains weight loss long term pharminent May 15, 2026
Clinical Data REGENXBIO slumps after serious side effects mar Duchenne gene therapy results pharminent May 14, 2026
Pipeline Biogen takes tau Alzheimer’s therapy to Phase 3 despite mid-stage fail, prompting cautious optimism pharminent May 14, 2026
Regulatory With new data, Regenxbio to seek FDA approval of Duchenne gene therapy pharminent May 14, 2026
M&A / Deals Degron adds $40M to series A, supporting immunology plans for molecular glue platform pharminent May 14, 2026
Regulatory Regulatory round-up: A month of key FDA approvals for cancer drugs pharminent May 14, 2026
Policy / Pricing FDA’s leadership void leaves biotech with renewed ‘uncertainty’ pharminent May 13, 2026
Policy / Pricing UniQure, Replimune shares rise as FDA’s Makary exits, but path forward unchanged pharminent May 13, 2026
Clinical Data ECO 2026: REDEFINE-1 demonstrates CagriSema’s improvement in body composition pharminent May 13, 2026
Clinical Data Lilly maintains weight loss leadership as Foundayo, Zepbound keep pounds off after switching pharminent May 13, 2026
Clinical Data Novo Nordisk data shows oral semaglutide delivers significant weight loss in phase 3 trial pharminent May 13, 2026
Policy / Pricing Makary resigns, with Diamantas named as acting FDA commissioner pharminent May 12, 2026
